Recent legislative discussions include a bill to ban direct-to-consumer (DTC) prescription drug advertising, reflecting growing interest in tighter regulations, although legal challenges related to First Amendment protections are expected1.
The Trump administration has taken several actions aimed at lowering drug prices, primarily through a May 2025 executive order mandating price targets and direct price negotiations with pharmaceutical manufacturers25.
While executive actions have focused on drug pricing and transparency, recent regulatory reforms have already tightened requirements for DTC ads, such as mandating clear communication of side effects1.
Some lawmakers have separately proposed restricting DTC ads in a drug's first three years on the market, and increasing price transparency in such ads1.
There is no confirmation of a final rule or immediate executive order specifically restricting all DTC advertising from the Trump administration as of June 2025, but multiple policy initiatives signal increasing pressure on pharmaceutical marketing practices.12
Sources:
1. https://www.fiercepharma.com/marketing/sens-sanders-king-propose-legislation-would-ban-dtc-pharma-ads
2. https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-announces-actions-to-put-american-patients-first-by-lowering-drug-prices-and-stopping-foreign-free-riding-on-american-pharmaceutical-innovation/
5. https://www.statnews.com/2025/06/12/trump-administration-demands-drug-companies-start-negotiating-prices/